Navigation Links
Novavax CEO to Present at the World Vaccine Congress 2009, Lyon, France
Date:10/6/2009

ROCKVILLE, Md., Oct. 6 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr. Rahul Singhvi, President and CEO of Novavax, will be making two presentations at the World Vaccine Congress 2009 conference on October 7th, 2009 at the Palais des Congres de Lyon, Lyon, France. The first presentation by Dr. Singhvi titled, 'Innovative Approaches to RSV vaccine development and VLP based vaccines' will be presented under the 'FUTURE DIRECTION OF VACCINE R&D' section. The second presentation, 'How to advance manufacturing using scalable solutions' will be presented under the 'CELL CULTURE BASED PRODUCTION -- THE NEXT FRONTIER?' session.

ABOUT NOVAVAX

Novavax, Inc. (Nasdaq: NVAX) a clinical-stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in the Company's various filings with the Securities and Exchange Commission.

SOURCE Novavax, Inc.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Novavax Announces Board of Director Changes
2. NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine Candidate
3. NOVAVAX Virus-Like Particle Vaccine Protects Against 2009 Pandemic H1N1 Influenza Virus
4. Novavax Reports Second Quarter 2009 Financial Results
5. Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer
6. Novavax Announces Release Date of 2009 Second Quarter, Financial Results and Investor Conference Call
7. Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies
8. Novavax Announces Appointment of John J. Trizzino as Senior Vice President, International and Government Alliances
9. Novavax Announces Repayment of $5 Million of Convertible Debt
10. Cadila Pharmaceuticals Launches Joint Venture With Novavax in India
11. Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") ... for the six months ended June 30, 2014. ... dollars and presented under International Financial Reporting Standards ... , Announced top-line results related to the ... subjects enrolled in the Phase 2 iDEAL Study ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Intrinsic ... 13485:2003 certified, GAMP® 5 compliant imaging core lab, ... international Phase II clinical trial to assess a ... Throughout this trial, Intrinsic Imaging will provide comprehensive ... to, protocol and charter development, site qualification, site ...
(Date:8/28/2014)... Ind. A new research platform uses ... of tiny structures undergoing stress and heating, ... improve designs for microelectronics and batteries., This ... information about how heating and the surface ... properties. Researchers have discussed the merits of ...
(Date:8/28/2014)... , Aug. 28, 2014   SunTrust Robinson Humphrey ... industry veterans to its equity research team in ... ongoing expansion in equity research demonstrates our commitment ... insights to enhance their investment decision making," said ... STRH.  "We continue to make significant investments in ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3
... , , , , , Multiporator / Electroporator 2510 , , , ... Transformation Protocol , Protocol No. 4308 915.501 04/2002 ... , , , , , ... , Cell type , ...
... Kits , , ... Eppendorf Perfectprep Plasmid DNA Isolation Kits are designed to generate , ... automated fluorescent , sequencing, transfection, PCR, and other extremely ... In order to compare yields between our kits and the leading competitor, ...
... , Other important parameters for optimizing electroporation., , , , , , ... , Pulse length , ... Adjustment , of the electroporation buffer , ... Influence , of temperature , ...
Cached Biology Technology:Actinomyces viscosus 2Eppendorf Perfectprep Plasmid DNA Isolation , Kits 2Eppendorf Perfectprep Plasmid DNA Isolation , Kits 3Optimizing electroporation parameters 2
(Date:8/28/2014)... the developmental on-off switch for Streptomyces , a ... of the world,s naturally derived antibiotic medicines. , ... is possible to manipulate this switch to make nature,s ... August 28 in Cell , found that a ... a larger protein called BldD ultimately controls whether a ...
(Date:8/28/2014)... FASEB MARC (Maximizing Access to Research Careers) ... the American College of Sports Medicine,s Conference on ... in Miami, Florida. These awards are meant ... and scientists from underrepresented groups into the mainstream ... the participation of young scientists at the American ...
(Date:8/28/2014)... Dyslexia, the most commonly diagnosed learning disability in ... that occurs when the regions of the brain ... The use of non-invasive functional neuroimaging tools has ... dyslexia. However, most prior work has focused on ... a gap in our understanding of how multiple ...
Breaking Biology News(10 mins):Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3Dyslexic readers have disrupted network connections in the brain 2
... National data indicate that milk consumption has declined ... nutritional quality has more than doubled. Although this suggests ... in children,s diets, a new study suggests that in ... related to changes in their consumption of sodas and ...
... at the California Institute of Technology (Caltech) pioneered ... the immune system and neurodevelopmental disorders such as ... postmortem brains and of individuals with autism, as ... between alterations in the immune system and autism ...
... is a vital nutrient for pig growth, but pigs ... the University of Illinois has determined how adding various ... how pigs digest the phosphorus in four different feed ... bottom lines as well as for the environment. ...
Cached Biology News:Sugar-sweetened drinks are not replacing milk in kid's diets 2Sugar-sweetened drinks are not replacing milk in kid's diets 3Caltech researchers find evidence of link between immune irregularities and autism 2Caltech researchers find evidence of link between immune irregularities and autism 3Helping pigs to digest phosphorus 2Helping pigs to digest phosphorus 3
Mouse monoclonal antibody raised against a partial recombinant ALAS2. NCBI Entrez Gene ID = ALAS2...
Mouse monoclonal antibody raised against a partial recombinant QPCT. NCBI Entrez Gene ID = QPCT...
Mouse monoclonal antibody raised against a partial recombinant STAU2. NCBI Entrez Gene ID = STAU2...
... gun system, 220-240 V, is used for ... This handheld device employs an adjustable helium ... biomaterial-coated gold microcarriers from the inner wall ... target cells. This system has a 2 ...
Biology Products: